Please ensure Javascript is enabled for purposes of website accessibility

Why Heron Therapeutics Stock Is Crashing Today

By George Budwell – Dec 5, 2017 at 4:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heron bolsters its shrinking cash position with a $150 million public offering.

What happened

Heron Therapeutics (HRTX 4.14%), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average daily volume. This double-digit move lower was sparked by a $150 million public offering of its common stock.

Heron reportedly plans on using the proceeds from this secondary offering to support the ongoing commercial launches of its medicines for chemotherapy-induced nausea, Sustol and Cinvanti, as well as to fund its clinical activities.

A man watches a red arrow breaking through the floor.

Image source: Getty Images.

So what

Heron's sizable secondary offering shouldn't come as a shock to shareholders. After all, Sustol's commercial launch has been extremely underwhelming so far -- this year the drug is on track to rack up a mere $25 million to $30 million in net sales. As a result, Heron exited the most recent quarter with only $74 million in cash remaining in its coffers. That amount simply wasn't enough to support the commercial launch of Cinvanti, along with the late-stage clinical development of its experimental pain medicine, HTX-011.

Now what

Unfortunately, Heron still supports a rather questionable valuation, even after today's noteworthy decline. With a price-to-sales ratio of 38.4, for instance, Heron is easily one of the most expensive biotech stocks right now. Moreover, Heron isn't expected to experience a leap in revenue growth in the near future to bridge this valuation gap. The biotech, in fact, is currently trading at a whopping 12.6 times its projected 2018 sales.

Bottom line: The market appears to have put a little too much faith in Sustol's commercial potential right out of the gate, and reality is now starting to set in. Until this small-cap biotech stock sheds a lot more weight, it arguably isn't worth buying.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$4.02 (4.14%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.